James Samuel Shannon - 16 Jun 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Kevin Brennan, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
16 Jun 2025
Net transactions value
+$48,085
Form type
4
Filing time
18 Jun 2025, 16:57:19 UTC
Previous filing
12 Jun 2025
Next filing
03 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shannon James Samuel Director 828 WINTER STREET, SUITE 300, WALTHAM /s/ Kevin Brennan, Attorney-in-Fact 18 Jun 2025 0001485417

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLO Common Stock Purchase $30,870 +45,000 $0.6860 45,000 16 Jun 2025 Direct F1
transaction XLO Common Stock Purchase $17,215 +25,000 +56% $0.6886 70,000 17 Jun 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6799 to $0.6891 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6659 to $0.6991 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.